Okafor Ii, Ugwu Eo, Obi Sn, Odugu Bu
Department of Obstetrics and Gynecology, Enugu State University of Science and Technology Teaching Hospital, Parklane, Enugu, Nigeria.
Department of Obstetrics and Gynecology, College of Medicine, University of Nigeria, Enugu, Enugu State, Enugu Campus/University of Nigeria Teaching Hospital, Ituku/Ozalla, Enugu, Nigeria.
Ann Med Health Sci Res. 2014 Jul;4(4):615-8. doi: 10.4103/2141-9248.139344.
With the current World Health Organization (WHO) "Option B+" for prevention of mother to child transmission (PMTCT) of human immunodeficiency virus (HIV), virtual elimination of mother to child transmission (eMTCT) is highly achievable.
The aim of this study is to determine the rate of MTCT of HIV from mothers who started highly active antiretroviral therapy (HAART) for life from diagnosis during pregnancy to the exposed babies who had daily nevirapine in the first 6 weeks of life.
HIV positive mothers and their exposed babies who enrolled for the hospital PMTCT protocol from January 1, 2009 to December 31, 2011 were studied. The babies were tested for HIV using deoxyribo nucleic acid polymerase chain reaction test at 6 weeks, and then HIV rapid tests at 18 months.
A total of 5,946 booked mothers had HIV testing and counseling (HTC) within the study period. Two hundred and twenty-three (223/5946, 3.7%) were positive, out of which 188 (188/223, 84.3%) enrolled for the PMTCT interventions while 35 (35/223, 15.7%) did not enroll. Three of the enrollees were lost to follow up and two were referred to another PMCT center. Of the remaining 183 enrolled HIV positive mothers, one gave birth to a set of twins, giving a total of 184 exposed babies. There were two cases of intrauterine fetal death of unknown fetal HIV status. None of the 182 remaining babies evaluated for HIV testing tested positive to HIV.
With adequate suppression of maternal viral replication with HAART using the WHO Option B+, eMTCT of HIV is achievable in a developing country like Nigeria where infant breastfeeding is a norm.
按照世界卫生组织(WHO)目前预防人类免疫缺陷病毒(HIV)母婴传播(PMTCT)的“B+方案”,几乎可以实现母婴传播的完全消除(eMTCT)。
本研究旨在确定从孕期诊断后开始终身接受高效抗逆转录病毒疗法(HAART)的母亲到出生后前6周每日服用奈韦拉平的受感染婴儿的HIV母婴传播率。
对2009年1月1日至2011年12月31日期间登记参加医院PMTCT方案的HIV阳性母亲及其受感染婴儿进行了研究。婴儿在6周时使用脱氧核糖核酸聚合酶链反应检测进行HIV检测,然后在18个月时进行HIV快速检测。
在研究期间,共有5946名登记母亲接受了HIV检测和咨询(HTC)。其中223名(223/5946,3.7%)呈阳性,其中188名(188/223,84.3%)登记参加了PMTCT干预,而35名(35/223,15.7%)未登记。3名登记参与者失访,2名被转诊至另一个PMCT中心。在其余183名登记的HIV阳性母亲中,有1名产下一对双胞胎,共有184名受感染婴儿。有2例宫内胎儿死亡,胎儿HIV状况不明。其余182名接受HIV检测评估的婴儿均未检测出HIV阳性。
在像尼日利亚这样婴儿母乳喂养很普遍的发展中国家,通过使用WHO的B+方案,用HAART充分抑制母体病毒复制,可以实现HIV的母婴传播完全消除。